# Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients

> **NCT06665568** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Zurich** · enrollment: 100 (estimated)

## Conditions studied

- Depressive Symptoms Mild to Moderate in Severity
- Anxiety
- Quality of Life (QOL)
- Caregiver Burden
- Sleep Quality

## Interventions

- **DRUG:** Intranasal ketamine hydrochloride

## Key facts

- **NCT ID:** NCT06665568
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06665568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06665568, "Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06665568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*